Lycia Therapeutics

We're building the leading extracellular protein degradation company, leveraging our lysosomal targeting chimeras, or LYTAC, platform.

[Lycia Therapeutics @LyciaTx]

Graves’ disease affects millions, and no two journeys are the same. This International Thyroid Awareness Week, we support those seeking answers and better care. Your thyroid health matters. #Thyroid #GravesDisease

[Lycia Therapeutics @LyciaTx]

It’s #FoodAllergy Awareness Week. Over 33M Americans face life-threatening food allergies. Limited treatments leave many at risk. Join us in the fight for better solutions through research, education, and advocacy: https://t.co/oq6i5Jltbq

[Lycia Therapeutics @LyciaTx]

It's National #Asthma & #Allergy Awareness Month, a time to support those living with allergic conditions. At Lycia, we’re working to advance new treatments for asthma, food allergies, and chronic urticaria.

Together, let’s drive progress.

[Lycia Therapeutics @LyciaTx]

This #PatientExperienceWeek, we celebrate more than care; we celebrate collaboration. Patient insights and lived experiences are essential to shaping clinical trials that are truly inclusive, accessible, and meaningful.

When we listen, we learn and do better for everyone.

[Lycia Therapeutics @LyciaTx]

At Lycia, we’re pioneering a new approach to treating previously undruggable diseases. If you’re passionate about pushing the boundaries of science, we’re hiring!

Check out our job openings: https://t.co/zoTzNIRrO5

#LifeAtLycia #BiotechCareers

[Lycia Therapeutics @LyciaTx]

We stood up for science! On Friday, our team joined the #StandUpForScience2025 Rally to support research & innovation. Amazing energy, inspiring voices—let’s keep advocating for science! #ScienceMatters #ResearchForAll #StandUpForScience

[Lycia Therapeutics @LyciaTx]

Science fuels progress, drives innovation, and improves lives. We’re proud to stand up for research and evidence-based decision-making at the #StandUpForScience2025 Rally —where our founder, Nobel Laureate @CarolynBertozzi will be a featured speaker.

Join us!

[Lycia Therapeutics @LyciaTx]

Lycia’s leadership will attend the 2025 AAAAI/WAO Joint Congress in San Diego, Feb 28 – Mar 3.

We’re excited to discuss the latest in allergy & immunology R&D and share how our LYTAC platform is shaping the future of targeted protein degradation. Let's connect at #AAAAI2025!

[Lycia Therapeutics @LyciaTx]

Please join us in welcoming Chin Lee, MD, MPH, as Lycia’s Chief Medical Officer to help advance our pipeline of LYTAC-based therapies for autoimmune diseases.

Welcome, Dr. Lee! https://t.co/NaC3JqA7i0

[Lycia Therapeutics @LyciaTx]

Last week, we partnered with Biocom’s Generation #STEAM to inspire the next generation! We hosted Tennyson HS students for lab tours, career panels, and hands-on activities.

Our team also assembled 209 STEAM kits for Martin Elementary and BioLink Depot. Proud to give back!

[Lycia Therapeutics @LyciaTx]

Our CataLYTAC research is live on @biorxivpreprint.

CataLYTACs offer faster, deeper, and longer-lasting degradation of soluble targets, showing the power of catalytic protein degradation.

Read more about this progress in extracellular therapies here: https://t.co/0xYdNHWYCq

[Lycia Therapeutics @LyciaTx]

Our CEO, Aetna Wun Trombley, will participate in a panel on Wed., June 5 at #BIO2024, moderated by Mariana Mihalusova @Venrock, discussing novel approaches to co-opting biological processes - incl. our LYTAC extracellular protein degraders - to drug a spectrum of diseases. #BIO24

[Lycia Therapeutics @LyciaTx]

A big thanks to @NYSE for celebrating our Series C financing on the trading floor last week! We're excited to continue advancing our lead LYTAC degraders toward the clinic for #autoimmune and #inflammatory diseases!

[Lycia Therapeutics @LyciaTx]

We're excited to welcome Andrew Gottesdiener, M.D., Partner @Venrock to our Board of Directors, concurrent with our $106.6M Series C financing, announced yesterday.

Read the press release:
https://t.co/f0lyFDqH10

[Lycia Therapeutics @LyciaTx]

Thanks, @medcitynews @frankvinluan for covering our Series C financing and our continued progress advancing our lead LYTAC extracellular protein degrader programs toward the clinic for #autoimmune and #inflammatory diseases.

Read article: https://t.co/WT5pkxemN4

[Lycia Therapeutics @LyciaTx]

We're thrilled to announce the completion of a $106.6 million Series C financing to progress our lead LYTAC extracellular protein degraders into the clinic for unmet needs in #autoimmune and #inflammatory diseases.

Read release: https://t.co/f0lyFDqH10

[Lycia Therapeutics @LyciaTx]

Our President & CEO @aetnawun will present at the Jefferies Healthcare Conference on Wed., June 7, describing out LYTAC platform to discover & develop first-in-class therapeutics that degrade extracellular & membrane bound proteins. https://t.co/R9odkoOn5u #JefferiesHealthcare

[Lycia Therapeutics @LyciaTx]

On #IWD2023, we recognize the amazing women of Lycia, and we join with women & their allies across the world to celebrate this year's theme: #EmbraceEquity
Today and every day, we're proud to be proactively building a workplace that is #diverse, #equitable & #inclusive.

[Lycia Therapeutics @LyciaTx]

Today, we celebrate International Day of Women and Girls in Science. Lycia is a woman-founded and woman-led company. We thrive here in our culture of diversity, equity and inclusion.

Learn more about the day: https://t.co/01kW5OsUoZ

#EquityInScience #WomeninScience

[Lycia Therapeutics @LyciaTx]

What a thrill it was for us to celebrate your Nobel Prize with you, @CarolynBertozzi!! We're so honored to have the opportunity to work with you, learn from you, and build on your incredible work! Excited for all the possibilities ahead for #LYTAC medicines!